TCBP Financial Statements From 2010 to 2025

TCBP Stock  USD 1.75  0.02  1.16%   
TC BioPharm financial statements provide useful quarterly and yearly information to potential TC BioPharm Holdings investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on TC BioPharm financial statements helps investors assess TC BioPharm's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting TC BioPharm's valuation are summarized below:
Gross Profit
3.8 M
Market Capitalization
360.4 K
Enterprise Value Revenue
1.8297
Revenue
2.9 M
Earnings Share
(192.95)
There are currently one hundred twenty fundamental measures for TC BioPharm that can be evaluated and compared over time across peers in the sector. Investors and active traders are advised to double-check TC BioPharm's latest fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction. As of 03/18/2025, Market Cap is likely to drop to about 53.8 B. In addition to that, Enterprise Value is likely to drop to about 53.8 B

TC BioPharm Total Revenue

0.0

Check TC BioPharm financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TC BioPharm's main balance sheet or income statement drivers, such as Interest Income of 1.9 K, Depreciation And Amortization of 638 K or Interest Expense of 90.7 K, as well as many indicators such as Price To Sales Ratio of 199, Dividend Yield of 0.0 or PTB Ratio of 86.71. TCBP financial statements analysis is a perfect complement when working with TC BioPharm Valuation or Volatility modules.
  
Check out the analysis of TC BioPharm Correlation against competitors.

TC BioPharm Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets10 M10.3 M9.8 M
Pretty Stable
Short and Long Term Debt Total1.5 M1.6 M3.8 M
Very volatile
Other Current Liabilities5.1 M2.8 M2.4 M
Slightly volatile
Total Current Liabilities9.4 M5.5 M5.8 M
Slightly volatile
Other Liabilities3.1 M1.7 M4.5 M
Slightly volatile
Property Plant And Equipment Net3.2 M2.4 M4.7 M
Slightly volatile
Accounts Payable1.2 M2.1 M899.1 K
Slightly volatile
Cash2.3 M2.8 M1.5 M
Slightly volatile
Non Current Assets Total3.6 M2.9 M5.1 M
Slightly volatile
Cash And Short Term Investments2.3 M2.8 M1.5 M
Slightly volatile
Net Receivables1.4 M1.1 M2.4 M
Slightly volatile
Common Stock Shares Outstanding149.2 M142.1 M28 M
Slightly volatile
Liabilities And Stockholders Equity10 M10.3 M9.8 M
Pretty Stable
Non Current Liabilities Total1.3 M1.3 M6.5 M
Slightly volatile
Capital Lease Obligations2.1 M1.6 MM
Slightly volatile
Other Current Assets4.9 M4.7 M2.9 M
Very volatile
Total Liabilities10.4 M5.6 M12.2 M
Pretty Stable
Property Plant And Equipment Gross5.4 M6.1 M6.8 M
Slightly volatile
Total Current Assets5.2 M6.6 M4.6 M
Slightly volatile
Capital Stock1.8 K1.9 K1.3 M
Slightly volatile
Short Term Debt333.6 K351.1 K883.3 K
Pretty Stable
Intangible Assets523.9 K707.4 K397.7 K
Slightly volatile
Common Stock1.8 K1.9 K1.2 M
Slightly volatile
Property Plant Equipment3.4 M2.7 M4.8 M
Slightly volatile
Short and Long Term Debt558.7 K588.1 K5.3 M
Slightly volatile

TC BioPharm Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Income1.9 KK14.3 K
Slightly volatile
Depreciation And Amortization638 K567 K833.3 K
Slightly volatile
Interest Expense90.7 K95.5 K844.2 K
Slightly volatile
Selling General Administrative5.1 M7.4 M3.9 M
Slightly volatile
Gross Profit3.1 M4.4 M3.3 M
Very volatile
Other Operating Expenses6.2 M6.2 M8.9 M
Slightly volatile
Research Development5.9 MMM
Slightly volatile
Total Operating Expenses6.2 M6.2 M8.9 M
Slightly volatile
Reconciled Depreciation736.6 K569.7 K878.2 K
Slightly volatile
Selling And Marketing Expenses321.9 K362.1 K394.8 K
Slightly volatile

TC BioPharm Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow2.4 M4.3 M5.1 M
Slightly volatile
Depreciation732.8 K569.7 K876.4 K
Slightly volatile
Capital Expenditures94.4 K99.3 K1.4 M
Slightly volatile
Issuance Of Capital Stock3.3 M4.8 M3.2 M
Pretty Stable
Total Cash From Financing Activities8.9 M9.8 M5.5 M
Slightly volatile
End Period Cash Flow2.3 M2.8 M1.5 M
Slightly volatile
Change To Inventory2.3 M2.5 M2.8 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1992093.4 K
Slightly volatile
Days Sales Outstanding9.1810.3311.2615
Slightly volatile
Average Payables836.1 K1.2 M786 K
Slightly volatile
Stock Based Compensation To Revenue0.250.260.2645
Slightly volatile
Capex To Depreciation0.190.21.4546
Slightly volatile
EV To Sales39.8 K41.9 K683.1 K
Slightly volatile
Sales General And Administrative To Revenue1.141.951.1819
Slightly volatile
Research And Ddevelopement To Revenue3.012.272.5534
Very volatile
Capex To Revenue0.06840.0720.3879
Slightly volatile
Cash Per Share0.0170.01790.0953
Very volatile
Income Quality2.51.611.8542
Slightly volatile
Intangibles To Total Assets0.04260.0620.0402
Slightly volatile
Current Ratio0.611.080.9553
Slightly volatile
Receivables Turnover25.4428.6231.207
Slightly volatile
Capex Per Share0.0010.0010.1145
Slightly volatile
Revenue Per Share0.20.250.2808
Slightly volatile
Interest Debt Per Share0.01590.01680.399
Very volatile
Debt To Assets0.220.230.3865
Pretty Stable
Operating Cycle9.1810.3311.2615
Slightly volatile
Ebt Per Ebit1.060.560.9852
Pretty Stable
Long Term Debt To Capitalization0.290.320.3512
Slightly volatile
Quick Ratio0.611.080.9553
Slightly volatile
Net Income Per E B T0.860.970.8524
Pretty Stable
Cash Ratio0.250.470.28
Slightly volatile
Cash Conversion Cycle9.1810.3311.2615
Slightly volatile
Days Of Sales Outstanding9.1810.3311.2615
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.181.161.212
Slightly volatile
Fixed Asset Turnover0.551.050.6878
Slightly volatile
Debt Ratio0.220.230.3865
Pretty Stable
Price Sales Ratio1992093.4 K
Slightly volatile
Asset Turnover0.330.390.3312
Very volatile

TC BioPharm Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap53.8 B56.7 B2.1 T
Slightly volatile
Enterprise Value53.8 B56.7 B2.1 T
Slightly volatile

TCBP Fundamental Market Drivers

Cash And Short Term Investments2.5 M

TCBP Upcoming Events

6th of May 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of May 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About TC BioPharm Financial Statements

TC BioPharm shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although TC BioPharm investors may analyze each financial statement separately, they are all interrelated. The changes in TC BioPharm's assets and liabilities, for example, are also reflected in the revenues and expenses on on TC BioPharm's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-274.8 K-261.1 K
Stock Based Compensation To Revenue 0.26  0.25 
Sales General And Administrative To Revenue 1.95  1.14 
Research And Ddevelopement To Revenue 2.27  3.01 
Capex To Revenue 0.07  0.07 
Revenue Per Share 0.25  0.20 
Ebit Per Revenue(3.61)(3.80)

Pair Trading with TC BioPharm

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if TC BioPharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in TC BioPharm will appreciate offsetting losses from the drop in the long position's value.

Moving together with TCBP Stock

  0.83ME 23Andme HoldingPairCorr

Moving against TCBP Stock

  0.92VALN Valneva SE ADR Earnings Call TodayPairCorr
  0.76VIGL Vigil NeurosciencePairCorr
  0.69DMAC DiaMedica TherapeuticsPairCorr
  0.68DVAX Dynavax TechnologiesPairCorr
  0.61EQ EquilliumPairCorr
The ability to find closely correlated positions to TC BioPharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace TC BioPharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back TC BioPharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling TC BioPharm Holdings to buy it.
The correlation of TC BioPharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as TC BioPharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if TC BioPharm Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for TC BioPharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for TCBP Stock Analysis

When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.